http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 04:25:05 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Barclays+Starts+Indivior+%28INDV%29+at+Overweight/26661953.html <p>Barclays analyst Glen Santangelo initiates coverage on Indivior (NASDAQ: INDV) with a Overweight rating and a price target of $46.00.</p><p>The analyst comments: “Indivior has undergone a transformation following the appointment of CEO Joe Ciaffoni last summer, the rollout of the Indivior Action Agenda and the transition to a US listing earlier this year. While these positive developments have certainly contributed to the stock's impressive performance – +168% over the past 12 months (S&P +25%) – we believe the company’s core fundamentals and outlook remain somewhat underappreciated. Looking ahead, we expect additional beats and raises plus repo, which should contribute to http://www.streetinsider.com/New+Coverage/Barclays+Starts+Indivior+%28INDV%29+at+Overweight/26661953.html Thu, 18 Jun 2026 04:25:05 -0400 INDV http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Indivior+%28INDV%29+at+Overweight/26661953.html <p>Barclays analyst Glen Santangelo initiates coverage on Indivior (NASDAQ: INDV) with a Overweight rating and a price target of $46.00.</p><p>The analyst comments: “Indivior has undergone a transformation following the appointment of CEO Joe Ciaffoni last summer, the rollout of the Indivior Action Agenda and the transition to a US listing earlier this year. While these positive developments have certainly contributed to the stock's impressive performance – +168% over the past 12 months (S&P +25%) – we believe the company’s core fundamentals and outlook remain somewhat underappreciated. Looking ahead, we expect additional beats and raises plus repo, which should contribute to http://www.streetinsider.com/Analyst+Comments/Barclays+Starts+Indivior+%28INDV%29+at+Overweight/26661953.html Thu, 18 Jun 2026 04:25:05 -0400 INDV http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+11++Filed+by%3A+Heidbreder+Christian/26640840.html si-local-file:///var/storage/secattach/20260612/26640840.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+11++Filed+by%3A+Heidbreder+Christian/26640840.html Fri, 12 Jun 2026 16:11:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+11++Filed+by%3A+Heidbreder+Christian/26640840.html si-local-file:///var/storage/secattach/20260612/26640840.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+11++Filed+by%3A+Heidbreder+Christian/26640840.html Fri, 12 Jun 2026 16:11:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Heidbreder+Christian/26634242.html si-local-file:///var/storage/secattach/20260611/26634242.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Heidbreder+Christian/26634242.html Thu, 11 Jun 2026 11:20:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Heidbreder+Christian/26634242.html si-local-file:///var/storage/secattach/20260611/26634242.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Heidbreder+Christian/26634242.html Thu, 11 Jun 2026 11:20:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+08++Filed+by%3A+Preblick+Ryan/26626149.html si-local-file:///var/storage/secattach/20260610/26626149.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+08++Filed+by%3A+Preblick+Ryan/26626149.html Wed, 10 Jun 2026 06:04:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+08++Filed+by%3A+Preblick+Ryan/26626149.html si-local-file:///var/storage/secattach/20260610/26626149.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+Jun+08++Filed+by%3A+Preblick+Ryan/26626149.html Wed, 10 Jun 2026 06:04:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144A++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616927.html si-local-file:///var/storage/secattach/20260608/26616927.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616927.html Mon, 08 Jun 2026 15:24:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144A++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616927.html si-local-file:///var/storage/secattach/20260608/26616927.html http://www.streetinsider.com/SEC+Filings/Form++144A++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616927.html Mon, 08 Jun 2026 15:24:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616559.html si-local-file:///var/storage/secattach/20260608/26616559.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616559.html Mon, 08 Jun 2026 13:58:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616559.html si-local-file:///var/storage/secattach/20260608/26616559.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Preblick+Ryan/26616559.html Mon, 08 Jun 2026 13:58:00 -0400 INDV O.19233790 http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Press+Releases/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html <ul type="disc"><li><em>Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.</em></li><li><em>In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine</em></li></ul> <p>RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse http://www.streetinsider.com/Globe+Newswire/New+Studies+Show+Adherence+to+Monthly+Injectable+Buprenorphine+is+Associated+with+Relapse+Reduction+and+Lower+Healthcare+Utilization/26525667.html Wed, 20 May 2026 09:00:00 -0400 A.50216685 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Indivior+Pharmaceuticals++For%3A+May+13/26504755.html si-local-file:///var/storage/secattach/20260515/26504755.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Indivior+Pharmaceuticals++For%3A+May+13/26504755.html Fri, 15 May 2026 16:03:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Indivior+Pharmaceuticals++For%3A+May+13/26504755.html si-local-file:///var/storage/secattach/20260515/26504755.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Indivior+Pharmaceuticals++For%3A+May+13/26504755.html Fri, 15 May 2026 16:03:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Madison+Avenue+Partners%2C+LP/26500671.html si-local-file:///var/storage/secattach/20260515/26500671.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Madison+Avenue+Partners%2C+LP/26500671.html Fri, 15 May 2026 09:19:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Madison+Avenue+Partners%2C+LP/26500671.html si-local-file:///var/storage/secattach/20260515/26500671.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Indivior+Pharmaceuticals+++++++++++++++Filed+by%3A+Madison+Avenue+Partners%2C+LP/26500671.html Fri, 15 May 2026 09:19:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+12++Filed+by%3A+Thompson+Juliet/26494998.html si-local-file:///var/storage/secattach/20260514/26494998.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+12++Filed+by%3A+Thompson+Juliet/26494998.html Thu, 14 May 2026 16:12:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+12++Filed+by%3A+Thompson+Juliet/26494998.html si-local-file:///var/storage/secattach/20260514/26494998.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+12++Filed+by%3A+Thompson+Juliet/26494998.html Thu, 14 May 2026 16:12:00 -0400 INDV O.19233790 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+13++Filed+by%3A+Kingsley+Stuart+A/26494945.html si-local-file:///var/storage/secattach/20260514/26494945.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Indivior+Pharmaceuticals++For%3A+May+13++Filed+by%3A+Kingsley+Stuart+A/26494945.html Thu, 14 May 2026 16:11:00 -0400 INDV O.19233790